Table 3. The cytotoxic activity of novel 1,2,3-triazolyloxime substituted-1,2,3-triazolyl sulfonamides (7a–o) on normal mouse fibroblast (L929), human hepatocellular carcinoma (Hep3B), and human lung carcinoma (A549) cell lines.
| Compounds ID | IC50a (μM) | S I e | |||
|---|---|---|---|---|---|
| L929b | Hep3Bc | A549d | Hep3B/A549 | A549/Hep3B | |
| 7a | 241.4 ± 0.2 | NDg | NDg | NDg | NDg |
| 7b | 32.3 ± 0.2 | 54.6 ± 9.9 | 94.2 ± 0.1 | 0.6 | 1.7 |
| 7c | 31.1 ± 0.1 | 22.4 ± 0.1 | 38.8 ± 0.4 | 0.6 | 1.7 |
| 7d | NDg | 132.7 ± 0.1 | 21.1 ± 0.3 | 6.3 | 0.2 |
| 7e | 48.8 ± 0.1 | 72.9 ± 0.1 | 29.4 ± 0.1 | 2.5 | 0.4 |
| 7f | 2.9 ± 0.6 | 47.1 ± 0.2 | 14.2 ± 0.1 | 3.3 | 0.3 |
| 7g | 28.0 ± 0.2 | 140.5 ± 0.7 | 9.1 ± 0.2 | 15.4 | 0.1 |
| 7h | 53.9 ± 0.1 | 35.9 ± 0.1 | 11.5 ± 0.1 | 3.1 | 0.3 |
| 7i | 62.9 ± 0.1 | 53.4 ± 0.1 | 13.6 ± 0.1 | 3.9 | 0.3 |
| 7j | 349.3 ± 5.5 | 14.5 ± 0.1 | 31.2 ± 0.1 | 0.5 | 2.2 |
| 7k | NDg | 117.4 ± 0.1 | 17.5 ± 0.3 | 6.7 | 0.1 |
| 7l | 99.0 ± 4.1 | 7.4 ± 0.2 | 10.8 ± 0.1 | 0.7 | 1.5 |
| 7m | 8.2 ± 3.4 | 5.5 ± 1.2 | 6.0 ± 0.4 | 0.9 | 1.1 |
| 7n | NDg | 6.9 ± 0.9 | 5.9 ± 0.8 | 1.2 | 0.9 |
| 7o | 48.7 ± 0.1 | 5.7 ± 1.0 | 9.1 ± 0.3 | 0.6 | 1.6 |
| 5-FUf | 14.0 ± 0.1 | 60.6 ± 0.1 | 100.3 ± 0.1 | — | — |
a
IC50 values are the concentration of novel 1,2,3-triazolyloxime substituted-1,2,3-triazolyl sulfonamides (7a–o) that reduces the cell viability to 50%, measured at 24 hours. The test results were expressed as the mean of triplicate assays.
b
Mouse fibroblast cell line.
c
Human hepatocellular carcinoma cell line.
d
Human lung carcinoma cell line.
e
Selectivity index.
f
5-Fluorouracil.
g
Not determined.